Analyst Price Targets — CRDL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 23, 2024 6:52 am | Edward Nash | Canaccord Genuity | $8.00 | $2.24 | StreetInsider | Cardiol Therapeutics (CRDL) PT Raised to $8 at Canaccord Genuity |
Latest News for CRDL
• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion. TORONTO, July 14, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of its Phase II…
TORONTO, July 9, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the B. Riley Securities Mind, Muscle & Vision Summit in Boston, MA, on July 16, 2026, at 12:20 p.m.
TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast on June 24, 2026. Shareholders voted overwhelmingly in favour of all…
TORONTO, June 23, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, announces that the Company's virtual Annual General Meeting of Shareholders (the "AGM") will be webcast on June 24, 2026, at 4:30 p.m. EDT. Cardiol Therapeutics' 2026 AGM When: June 24,…
TORONTO, May 14, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ in New York, NY, on May 19, 2026, at 1:30…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for CRDL.
Senate Trading
No Senate trades found for CRDL.
U.S. House Trading
No House trades found for CRDL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.